Gastroenterology

Even though COVID-19 infection disproportionately impacts minority patients, there’s no indication that vaccine intention differs depending on race in IBD patients.

This study found that compared with the general population, the prevalence of celiac disease in people with type 1 diabetes mellitus is increased.

Dr. Feuerstadt presented data about RBX2660 during the recent ACG 2021 meeting.

In his lecture, The End of the Beginning: Megatrends in Gastroenterology, William Chey, MD, emphasizes the importance of a multidisciplinary integrated care approach to treating IBS.

An absence of urgency was associated with greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.

Approximately 88% of patients treated with SER-109 achieved a sustained clinical response at 8 weeks.

A new study presented at ACG 2021 shows microbiome therapeutic CP101 effective in preventing recurrent CDI by increasing intestinal microbiome diversity.

Patients in the open-label extension of the OASIS study saw increases in Inflammatory Bowel Disease Questionnaire (IBDQ) scores.

PROSE allows patients to report their symptoms of dysphagia in real-time.

Investigators found fistulizing Crohn’s disease increases the healthcare burden and lengthens the duration of hospital stays in patients with acute kidney injuries.

Volume of waiting list registrations and DDLTs for alcoholic hepatitis exceeded expected trends by a mean of 59.5% in waiting list registrations and 62.0% in DDLTs

Biologic therapies show promising results of clinical remission in patients with Crohn's disease.

It can be challenging to find a suitable donor for fecal microbiota transplantation.

Dr. Aljaras talks about the importance of focusing on diet when examining irritable bowel syndrome.

RBX2660 is a a standardized, stabilized, investigational microbiota-based live therapeutic being studied for the treatment of C difficile infections.

Patients with Crohn's disease often also suffer from kidney dysfunction.

This patient group had higher odds of death and longer lengths of hospital stays.

Patients in both the ADVANCE and MOTIVATE studies achieved enhanced clinical response and endoscopic response.

Hypertension rates were low in both ulcerative colitis and multiple sclerosis patients treated with ozanimod, regardless of concurrent SNRI/SSRI use.

Many of the measures put in place because of COVID-19 have also helped to reduce the rates of C difficile infections.

There was a higher risk of type 2 diabetes in patients with fibrosis stage F4 compared to patients with stage F0 or F2.

Recent studies have shown the majority of potential FMT donors are ultimately rejected.

Recurrent CDI, severe CDI, and the number of stools were linked to lower Cdiff32 scores.

C difficile was found on 45% of shoe soles and 26.2% of private residences.

The 4 factors included baseline body mass index, fibrosis-4 index, albumin level at SVR, and alpha-foetoprotein level at SVR.